First report of successful treatment for hemoglobin Bristol-Alesha by hemopoietic stem cell transplantation

Ann Hematol. 2022 Mar;101(3):617-619. doi: 10.1007/s00277-021-04721-7. Epub 2021 Dec 1.

Abstract

HBB gene mutations lead to many kinds of diseases, of which, except for the two most common diseases of thalassemia and sickle cell anemia, rare kinds of hemolytic anemia, such as hemoglobin Bristol-Alesha, are rarely reported, no ideal treatment in clinic. A child suffered from chronic recurrent hemolytic attacks and the related genes of hereditary hemolytic anemia were detected on her. Hematopoietic stem cell transplantation was conducted in the treatment of the patient. The patient was diagnosed as hemoglobin Bristol-Alesha and achieved complete recovery after hematopoietic stem cell transplantation. For Bristol-Alesha, without characteristic clinical manifestation and specific biochemical examination, diagnosis is dependent on the gene mutation detection and hematopoietic stem cell transplantation is an effective and curable method.

Keywords: Child; HBB gene; Hematopoietic stem cell transplantation; Hemolytic anemia; Heredity.

Publication types

  • Case Reports

MeSH terms

  • Anemia, Hemolytic, Congenital / genetics
  • Anemia, Hemolytic, Congenital / therapy*
  • Female
  • Hematopoietic Stem Cell Transplantation*
  • Hemoglobinopathies / genetics
  • Hemoglobinopathies / therapy*
  • Hemoglobins, Abnormal / genetics*
  • Humans
  • Infant
  • Treatment Outcome

Substances

  • Hemoglobins, Abnormal
  • hemoglobin Alesha
  • hemoglobin Bristol